Immunotherapy with Low-Dose Interleukin 2 in Neuroblastoma
Author Information
Author(s): A Pession, A Prete, F Locatelli, S Pierinelli, AL Pession, R Maccario, E Magrini, B De Bernardi, P Paolucci, G Paolucci
Primary Institution: Clinica Pediatrica, Osp. S. Orsola-Malpighi Universita di Bologna
Hypothesis
Can low doses of recombinant human interleukin 2 (rHuIL-2) effectively control minimal residual disease in children with neuroblastoma after high-dose chemotherapy and autologous stem cell transplantation?
Conclusion
Low doses of rHuIL-2 are well tolerated and can help control minimal residual disease in children with high-risk neuroblastoma after intensive treatment.
Supporting Evidence
- 12 out of 17 patients are alive and well after treatment.
- The 2-year event-free survival rate was 67%.
- The overall survival rate was 92%.
- Patients showed an increase in T lymphocytes and natural killer cells after treatment.
Takeaway
This study tested a medicine called interleukin 2 to help kids with a type of cancer called neuroblastoma feel better after strong treatments. It worked pretty well without making them too sick.
Methodology
Patients received low doses of rHuIL-2 after high-dose chemotherapy and autologous stem cell transplantation, with treatment monitored for safety and effectiveness.
Potential Biases
Potential bias due to lack of a control group.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
12 male and 5 female patients with a median age of 52 months.
Want to read the original?
Access the complete publication on the publisher's website